72 citations
,
January 2003 in “American Journal of Pathology” This study found that the co-activator CBP enhances the agonistic action of hydroxyflutamide on androgen receptors, suggesting a mechanism for therapy resistance in prostate cancer.
Flutamide helps with prostate cancer and some skin conditions but can harm the liver.
3 citations
,
May 2016 in “Gynecological Endocrinology” This study found that while flutamide was very effective in improving hirsutism in women over long-term treatment, a high incidence of adverse effects led to a majority discontinuing the therapy.
116 citations
,
May 1992 in “The American Journal of Medicine” This study found that flutamide-induced liver toxicity in prostate cancer patients was very rare, occurring in only 0.18% of cases with clinical manifestations, and symptoms resolved after discontinuing the drug.
29 citations
,
July 2012 in “Fertility and Sterility” This study observed that hepatotoxicity is a rare but possible event in hyperandrogenic young females treated with low- and ultralow-dose flutamide, regardless of dose or oral contraceptive use.